| Chief Investigator (UK):
||Dr Meriel Jenney
| Sponsor (UK):
||University of Birmingham
||Cancer Research UK (Trial Number CRUK/06/027)
| Disease Site:
| Trial Type:
||Clincial Trial of an Investigational Medicinal Product
|| Closed to recruitment
| UKCRN Study ID (if applicable):
| ClinicalTrials.gov identifier:
| Open to New Sites?
| Recruitment Start Date:
| Anticipated Recruitment End Date:
| CRCTU Trial Management Team:
||Children's Cancer Trials Team
| Trial Email Address:
A plain English summary of this trial can be found at on the Cancer Help website (see Other Websites below for the link)
The RMS 2005 trial is for children and young people who have rhabdomyosarcoma which is a cancer affecting muscle and soft tissue. There are different types of rhabdomyosarcoma some of which can be more difficult to treat. Children in the RMS 2005 trial receive treatment depending on their age; where the tumour is located; the size of the tumour and the type of rhabdomyosarcoma.
One of the aims of the trial is to see whether it is beneficial to give additional chemotherapy to children who have tumours which are more difficult to treat. These patients are randomly allocated to two groups: one group does not receive any further chemotherapy whilst the other group receives a further 6 months of ‘maintenance’ chemotherapy. This is relatively low dose chemotherapy that can be given as an outpatient. By following the two groups of patients doctors will be able to see whether the additional chemotherapy improves the outcome for these children or whether it just adds a greater burden of treatment with extra visits to the hospital with no difference in survival.
Please note that the trials team cannot give individual’s clinical advice. Patients and their families should contact their treating physician to discuss trials for which they may be eligible.
- View Trial Summary Document
- View Trial Protocol Document
Clinical trial protocols are complex technical documents which should only be used for the treatment of subjects taking part in the trial. Patients who are interested in taking part in the trial are advised to talk to their health care professional.
Investigators please ensure you have R&D approval for this specific version of the protocol before using as a reference.